Abstract
In this study, we prepared two different type complex groups. One of them is based on Schiff base (A1 , A2 and A3) Cd(II) complexes, another one is β-blockers (acebutolol (ACE), atenolol (ATE) and propranolol (PRO)) Cu(II) complexes. The ligands and their metal complexes were characterized by elemental analyses, mass spectra, 1H(13C) NMR spectra, FT-IR, UV-vis, conductivity measurements and thermal analysis studies. Protonation constants of the ligands and stability constants of their complexes were determined by potentiometric titration method at 25.00±0.02 oC under nitrogen atmosphere and ionic strength of 0.10 M sodium perchlorate. For the Schiff bases, the solvent was 50% DMSO – water; for the β-blockers, it was 50% methanol-water media. The effects of these properties on the observed inhibition of chemiluminescence and the analytical implications of the results are also discussed. Two sets of novel coordination compounds were found to inhibit the intense chemiluminescence reaction in DMSO solution between luminol and dioxygen in the presence of a strong base.
Keywords: Schiff base ligands, Complexes, β-blockers, Stability Constants, Potentiometric studies, Luminol chemiluminescence
Current Analytical Chemistry
Title: Investigations into the Inhibition of Luminol Chemiluminescence by some Novel Metal Complexes
Volume: 6 Issue: 2
Author(s): Aysegul Golcu, R. Alan Wheatley, Havva Demirelli, Mehmet Tumer and Mustafa Dolaz
Affiliation:
Keywords: Schiff base ligands, Complexes, β-blockers, Stability Constants, Potentiometric studies, Luminol chemiluminescence
Abstract: In this study, we prepared two different type complex groups. One of them is based on Schiff base (A1 , A2 and A3) Cd(II) complexes, another one is β-blockers (acebutolol (ACE), atenolol (ATE) and propranolol (PRO)) Cu(II) complexes. The ligands and their metal complexes were characterized by elemental analyses, mass spectra, 1H(13C) NMR spectra, FT-IR, UV-vis, conductivity measurements and thermal analysis studies. Protonation constants of the ligands and stability constants of their complexes were determined by potentiometric titration method at 25.00±0.02 oC under nitrogen atmosphere and ionic strength of 0.10 M sodium perchlorate. For the Schiff bases, the solvent was 50% DMSO – water; for the β-blockers, it was 50% methanol-water media. The effects of these properties on the observed inhibition of chemiluminescence and the analytical implications of the results are also discussed. Two sets of novel coordination compounds were found to inhibit the intense chemiluminescence reaction in DMSO solution between luminol and dioxygen in the presence of a strong base.
Export Options
About this article
Cite this article as:
Golcu Aysegul, Wheatley Alan R., Demirelli Havva, Tumer Mehmet and Dolaz Mustafa, Investigations into the Inhibition of Luminol Chemiluminescence by some Novel Metal Complexes, Current Analytical Chemistry 2010; 6 (2) . https://dx.doi.org/10.2174/157341110790945526
DOI https://dx.doi.org/10.2174/157341110790945526 |
Print ISSN 1573-4110 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6727 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Diabetes and Chronic Heart Failure: From Diabetic Cardiomyopathy to Therapeutic Approach
Endocrine, Metabolic & Immune Disorders - Drug Targets ENaC in the Brain - Future Perspectives and Pharmacological Implications
Current Molecular Pharmacology Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics Steroids and the Immune Response in Graves Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Selected Herbals for Sports Injuries
The Natural Products Journal Tacrolimus Treatment in Myasthenia Gravis
Current Drug Therapy Chemistry, Physiology, and Pharmacology of β-Adrenergic Mechanisms in the Heart. Why are β-Blocker Antiarrhythmics Superior?
Current Pharmaceutical Design Vitamin D Levels in Middle-Aged Patients with Obstructive Sleep Apnoea Syndrome
Current Vascular Pharmacology Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research Interactions of Biologically Active Factors and Vascular Mediators During Hypertension in Pregnancy
Current Hypertension Reviews Cardiovascular Effects of Phosphodiesterase 5 Inhibitors
Current Pharmaceutical Design Phytotherapy of Hypertension: An Updated Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Common Variants for Heart Failure
Current Genomics Pro-Stimulatory Role of Methemoglobin in Inflammation Through Hemin Oxidation and Polymerization
Inflammation & Allergy - Drug Targets (Discontinued) Stem Cell Gene Therapy for Chronic Renal Failure
Current Gene Therapy Therapeutic Role of Methanolic Extract of Ocimum basilicum L. Seeds and its Isolated Compound as Potent Antidiabetic and Antihyperlipidemic Agents
The Natural Products Journal Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design Uremia, Atherothrombosis and Malnutrition: The Role of L-arginine- Nitric Oxide Pathway
Cardiovascular & Hematological Disorders-Drug Targets Recent Updates of N-Type Calcium Channel Blockers with Therapeutic Potential for Neuropathic Pain and Stroke
Current Topics in Medicinal Chemistry